Merck & Co., Inc. (MRK) is recommended as one of the best cheap stocks for beginners. Leerink Partners analyst Daina Graybosch maintained a Buy rating for MRK due to its strategic position in the competitive landscape of antibody-drug conjugates (ADCs) for treating extensive-stage small cell lung cancer (ES-SCLC).

Merck’s I-DXd has a first-to-market advantage in global studies, supporting plans for accelerated approval in lung cancer treatment. Merck & Co., Inc. (MRK) is a biopharmaceutical company offering health solutions for animals and humans through vaccines and pharmaceutical products.

While MRK is a solid investment, some AI stocks may offer greater potential and less risk. For an undervalued AI stock with benefits from Trump-era tariffs, explore our report on the best short-term AI stock. Check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now” for more investment options.

Read more at Yahoo Finance: Leerink Partners Remains Bullish on Merck & Co. (MRK)